Shares of Dr Reddy’s Laboratories jumped nearly 8 percent on Wednesday after the drugmaker won a major legal battle against Indivior in the US.
A US court allowed Dr Reddy’s to sell generic version of Indivior Plc’s opioid treatment drug Suboxone in the US, its biggest market.
Nimish Mehta, founder and director of Research Delta Advisor, spoke to CNBC-TV18 on what this victory means for Dr. Reddy's Labs (DRL).
“In FY20, as far as my understanding is, earnings per share (EPS) definitely should be up by more than Rs 30 per share, maybe $70-100 million opportunity for DRL assuming that there has not been much competition,” he said on Wednesday.
Talking about whether DRL will see immediate competition from authorized generic and US-based Mylan for Suboxone, Mehta said, “Mylan has settled and also has an approval. So they will definitely launch along with DRL and their launch will not be an at-risk launch and they will be the biggest beneficiary of this. Teva also has a favourable ruling because of this but they don’t have an approval for an abbreviated new drug application (ANDA) version but they cannot launch because for ANDA they lost the litigation. So if Teva can get an approval tomorrow, they probably also can launch under 505(b)(2), which also will be at-risk. There is one more company Par Pharma was also settled, they also can launch but as and when they get an approval. So their launch also will be a normal launch which will not be an at-risk launch."
Have you signed up for Primo, our daily newsletter? It has all the stories and data on the market, business, economy and tech that you need to know.
First Published: IST